Đánh giá kết quả điều trị u lympho tế bào B lớn lan tỏa tái phát và kháng trị tại Viện Huyết học - Truyền máu Trung ương giai đoạn 2016 – 2022

Evaluation of treatment results for relapsed and refractory diffuse large B-cell lymphoma (DLBCL) at the National Institute of Hematology and Blood Transfusion for the period 2016-2022 and the relationship between prognostic factors and survival time. Patients and methods: 99 patients diagnosed with relapsed and resistant diffuse large B-cell lymphoma were first treated at the National Institute of Hematology and Blood Transfusion from 1/2016 to 6/2022. Results and conclusions: The disease occurs in both sexes (male/female: 2: 1), the average age is 50.62 ± 12.9 years. The overall response rate after 3 cycles was 58.6% (complete response: CR 23.2%), after 6 cycles 63.9% (CR 48.4%). Overall survival (OS) after 12 months was 56.6%; 45.8% after 24 months and 35.5% after 36 months. The 12-month event-free survival (EFS) was 63.1%; after 24 months is 44.7%; after 36 months is 38.3%. The group of patients with ECOG score 0-1 had better OS and EFS than the ECOG group > 2. The group with relapse ≥ 12 months had better OS and EFS than the group with relapse < 12 month with p < 0.05.